New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Insmed, Inc. (INSM) vs Moderna, Inc. (MRNA)

Insmed, Inc. and Moderna, Inc. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $79.6B against $31.6B — 2.5× the size. Insmed, Inc. grew revenue faster over the last twelve months: 240.0% against 13.1%. Insmed, Inc. has the higher net margin (−39.9% vs −110.5%) and the lower return on invested capital (−247.6% vs −35.1%). Across the 18 metrics below, Insmed, Inc. leads on 11 and Moderna, Inc. on 7.

Valuation

Metric INSM MRNA Biotechnology median
P/E n/m n/m 8.49
P/S 20.35 30.99 8.56
P/B 42.58 11.44 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 19.96 30.35 8.00
Earnings yield (2.00%) (3.63%) (35.81%)
Free cash flow yield (2.03%) (2.61%) (25.41%)

Profitability

Metric INSM MRNA Biotechnology median
Gross margin 84.40% 28.00% 70.18%
Operating margin (37.11%) (116.04%) 0.00%
Net margin (39.85%) (110.46%) 0.00%
Free cash flow margin (41.30%) (80.95%) 0.00%
Return on equity (72.45%) (34.50%) (51.58%)
Return on assets (26.41%) (21.79%) (45.91%)
Return on invested capital (247.55%) (35.12%) 0.00%

Growth

Metric INSM MRNA Biotechnology median
Revenue growth (TTM) 239.97% 13.13% 7.20%
EPS growth (last fiscal year) (15.26%) 21.77% 29.04%
Revenue growth, 5-year CAGR 29.83% 19.34% 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric INSM MRNA Biotechnology median
Debt to equity 0.78 0.52 0.00
Current ratio 2.86 3.62 4.79
Net debt to EBITDA 0.71 1.77 1.01

Dividend

Metric INSM MRNA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INSM MRNA Biotechnology median
Market cap 31.57b 79.59b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack